The FDA on March 5, 2021 granted accelerated approval to YESCARTA® for adult patients with Relapsed or Refractory Follicular Lymphoma (FL) after two or more lines of systemic therapy. YESCARTA® is a product of Kite Pharma, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
